DR. ASA ABELIOVICH, M.D.
Neurology at 168 St, New York, NY
License number
New York 219456
Category
Neurology
Type
Neurology
Address
Address
710 W 168Th St, New York, NY 10032
Phone
(212) 305-6939
(212) 305-1145 (Fax)
(212) 305-1145 (Fax)
Personal information
See more information about ASA ABELIOVICH at radaris.comName
Address
Phone
21 Claremont Ave, New York, NY 10027
21 Claremont Ave, New York, NY 10027
230 Riverside Dr, New York, NY 10025
Organization information
See more information about ASA ABELIOVICH at bizstanding.comAsa Abeliovich MD
630 W 168 St, New York, NY 10032
Industry:
Neurologist
Site:
Phone:
(212) 305-1130 (Phone)
Description:
There are 102 doctors at this site. Surgery is not performed at this site.
Asa Abeliovich
Professional information
Dr. Asa Abeliovich, New York NY - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Neurology)
Address:
710 W 168Th St, New York 10032
(212) 305-6939 (Phone), (212) 305-1145 (Fax)
(212) 305-6939 (Phone), (212) 305-1145 (Fax)
Certifications:
Neurology, 2002
Awards:
Healthgrades Honor Roll
Languages:
English, Russian, Spanish
Hospitals:
710 W 168Th St, New York 10032
NewYork-Presbyterian Hospital/Columbia University Medical Center
630 West 168Th St, New York 10032
NewYork-Presbyterian Hospital/Columbia University Medical Center
630 West 168Th St, New York 10032
Education:
Medical School
Harvard Medical School
Graduated: 1996
University Ca Sf School Of Med
Harvard Medical School
Graduated: 1996
University Ca Sf School Of Med
Professor At Columbia University
Position:
Professor at Columbia University
Location:
Greater New York City Area
Industry:
Medical Practice
Work:
Columbia University
-
Professor
Education:
Harvard Medical School 1986 - 1996
Asa Abeliovich, New York NY
Specialties:
Neurology
Work:
Trustees of Columbia University-Dept. of Neurology
710 W 168Th St, New York, NY 10032 New York Presbyterian Hospital / Columbia
630 W 168Th St, New York, NY 10032
710 W 168Th St, New York, NY 10032 New York Presbyterian Hospital / Columbia
630 W 168Th St, New York, NY 10032
Education:
Harvard University(1996)
Asa Abeliovich, New York NY
Specialties:
Neurologist
Address:
710 W 168Th St, New York, NY 10032
630 W 168Th St, New York, NY 10032
630 W 168Th St, New York, NY 10032
Methods To Treat Neurodegenerative Conditions Or Diseases By Targeting Components Of A Pten Signaling Pathway
US Patent:
2011018, Aug 4, 2011
Filed:
Mar 17, 2009
Appl. No.:
12/933186
Inventors:
Asa Abeliovich - New York NY, US
Keiichi Inoue - New York NY, US
Keiichi Inoue - New York NY, US
International Classification:
A61K 33/14, A61K 31/407, A61K 31/425, A61K 31/404, A61K 31/55, A61K 31/505, A61K 31/426, A61K 31/506, A61K 31/7052, A61P 25/00
US Classification:
424677, 514411, 514365, 514415, 51421301, 514256, 514418, 514215, 514414, 514371, 514275, 514 44 R
Abstract:
The disclosure provides that components of a PTEN cell signaling pathway may be utilized as therapeutic targets for treating, preventing, slowing the progression of or delaying the onset of a neurodegenerative disease or disorder. Such components that may be targeted include, phosphatase and tensin homologue (PTEN), glycogen synthase kinase 3 beta (GSK3β), and AKT. The subject matter disclosed herein relates to the therapeutic use of inhibitors of PTEN, inhibitors of GSK3β, or activators of AKT to treat a neurodegenerative disease or disorder in a subject. Compounds are disclosed which may be used in the methods provided.
Parkin-Associated Complex For Protecting Post-Mitotic Neurons From Excitotoxicity And Uses Thereof
US Patent:
2004024, Dec 9, 2004
Filed:
Feb 20, 2004
Appl. No.:
10/783780
Inventors:
Asa Abeliovich - New York NY, US
John Staropoli - New York NY, US
John Staropoli - New York NY, US
International Classification:
A61K038/48, C12N009/64
US Classification:
424/094630, 435/226000
Abstract:
The present invention provides a parkin-associated complex. The present invention further provides methods for promoting ubiquitination of cyclin E in neurons, for decreasing cyclin E in neurons, for treating or preventing neurodegeneration in a subject, and for protecting neurons from excitotoxicity. Additionally, the present invention provides a therapeutic composition, and use of the therapeutic composition in an animal model. The present invention further provides a method for identifying an agent which interacts with a parkin-associated complex, agents identified by this method, and use of a parkin-associated agent to protect neurons from excitotoxicity. Additionally, the present invention provides methods for determining whether a subject has neurodegeneration, for assessing the efficacy of therapy to treat neurodegeneration in a subject, and for assessing the prognosis of a subject who has neurodegeneration. Finally, the present invention provides a kit for use in detecting neurodegeneration.
Protecting Cell Therapy For Neurological Disorders Including Parkinson's Disease
US Patent:
2006017, Aug 3, 2006
Filed:
Jan 31, 2005
Appl. No.:
11/048391
Inventors:
Asa Abeliovich - New York NY, US
Cecile Martinat - New York NY, US
Cecile Martinat - New York NY, US
International Classification:
A61K 48/00, C12N 5/08
US Classification:
424093210, 435368000
Abstract:
The present invention provides compositions and methods for enhancing and improving cell therapies for neurological disorders including Parkinson's disease. Specifically, the present invention provides a cell or cells modified by viral vector compositions that allow for the over-expression and RNAi mediated knockdown of genes in vitro and in vivo. The present invention further provides cell therapy methods for treating or preventing neurodegeneration in a subject, and for protecting neurons from damage in the context of neurodegenerative disorders using the modified cells. Additionally, the present invention provides methods for purification and identification of mature dopamine neurons for cell therapy using fluorescent compounds including JHC1-64.
Methods For The Treatment Of Neurodegenerative Diseases Using Nmda Receptor Glycine Site Antagonists
US Patent:
2009000, Jan 1, 2009
Filed:
Mar 17, 2008
Appl. No.:
12/049782
Inventors:
Asa ABELIOVICH - New York NY, US
Assignee:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK - New York NY
International Classification:
A61K 49/00, A61K 31/47, A61K 31/55, A61K 31/5415, C12Q 1/68, A61P 25/00, C12N 5/00, A61K 31/5025, A61K 31/404, C12Q 1/48
US Classification:
424 92, 514312, 514313, 51421301, 5142232, 514248, 514419, 435 15, 435 6, 435375
Abstract:
The disclosure provides methods for treating a neurodegenerative disease by administering a NMDA receptor glycine site antagonist. Compounds that can be used in the methods are also provided. Methods are also provided for determining whether a compound inhibits activity of a Parkinson's Disease-associated mutant of leucine-rich repeat kinase-2 (LRRK2). The methods include assessing accumulation of axonal spheroid inclusions, branching and length of neuronal processes, and neuronal cell death.
Vector-Mediated Gene Regulation In Midbrain Dopamine Neurons
US Patent:
2006015, Jul 13, 2006
Filed:
Jan 12, 2005
Appl. No.:
11/034501
Inventors:
Asa Abeliovich - New York NY, US
Jean-Jacques Bacci - New York NY, US
Jean-Jacques Bacci - New York NY, US
International Classification:
A61K 48/00
US Classification:
424093200, 514044000
Abstract:
The present invention provides compositions and methods for vector mediated gene regulation in neurons. Specifically, the present invention provides therapeutic compositions comprising viral vectors that allow for the over-expression and RNAi mediated knockdown of genes in vivo. The present invention further provides methods for treating or preventing neurodegeneration in a subject, and for protecting neurons from damage in the context of neurodegenerative disorders. Additionally, the present invention provides a composition, and use of the composition in improving animal models of neurodegeneration.
Optimized Mirna Constructs
US Patent:
2014005, Feb 20, 2014
Filed:
Aug 25, 2011
Appl. No.:
13/818956
Inventors:
Asa Abeliovich - New York NY, US
Hervé Rhinn - New York NY, US
Toru Yamashita - New York NY, US
Hervé Rhinn - New York NY, US
Toru Yamashita - New York NY, US
International Classification:
C12N 15/113
US Classification:
514 44 R, 536 245, 536 231, 4353201, 435375, 536 253, 435 61
Abstract:
The invention provides optimized miRNA sequences and their therapeutic use. The invention provides optimized miRNA constructs for treatment of neurodegenerative diseases.